Sistema de Salut de Catalunya
Institut Català de la Salut
[Mosele MF] INSERM U981, Gustave Roussy, Villejuif, France. Department of Cancer Medicine, Gustave Roussy, Villejuif, France. [Westphalen CB] Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Germany. [Stenzinger A] Institute of Pathology, University Hospital Heidelberg and Center for Personalized Medicine (ZPM), Heidelberg, Germany. [Barlesi F] INSERM U981, Gustave Roussy, Villejuif. Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre. [Bayle A] Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre. Drug Development Department (DITEP), Gustave Roussy, Villejuif. Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif. Service de Biostatistique et Epidémiologie, Gustave Roussy, Villejuif. [Bièche I] Department of Genetics, Institut Curie, INSERM U1016, Université Paris Cité, Paris, France. [Dienstmann R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic—Central University of Catalonia, Vic, Spain. University of Vic—Central University of Catalonia, Vic, Spain. Oncoclínicas, São Paulo, Brazil. [Serrano C, Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-06-27T09:56:38Z
2024-06-27T09:56:38Z
2024-07
Advanced cancer; Next-generation sequencing; Precision medicine
Càncer avançat; Seqüenciació de nova generació; Medicina de precisió
Cáncer avanzado; Secuenciación de nueva generación; Medicina de precisión
Background Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour next-generation sequencing (NGS) for patients with advanced cancers in routine practice. Methods The group discussed the clinical impact of tumour NGS in guiding treatment decision using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) considering cost-effectiveness and accessibility. Results As for 2020 recommendations, ESMO recommends running tumour NGS in advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, and ovarian cancer. Moreover, it is recommended to carry out tumour NGS in clinical research centres and under specific circumstances discussed with patients. In this updated report, the consensus within the group has led to an expansion of the recommendations to encompass patients with advanced breast cancer and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary. Finally, ESMO recommends carrying out tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available. Conclusion Tumour NGS is increasingly expanding its scope and application within oncology with the aim of enhancing the efficacy of precision medicine for patients with cancer.
This project was funded by the European Society for Medical Oncology (no grant numbers are applicable).
Artículo
Versión publicada
Inglés
Medicina personalitzada; Càncer - Tractament; Càncer - Aspectes genètics; Seqüència de nucleòtids; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Genetic Techniques::Sequence Analysis::High-Throughput Nucleotide Sequencing; DISEASES::Neoplasms; Other subheadings::Other subheadings::/therapy; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas genéticas::análisis de secuencias::secuenciación de nucleótidos de alto rendimiento; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::/terapia
Elsevier
Annals of Oncology;35(7)
https://doi.org/10.1016/j.annonc.2024.04.005
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
